Clinical trials: Side Effect
Gastroparesis
Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis
Erythromycin is effectively used in the treatment of Gastroparesis (GP) patients. In susceptible patients however, it has been associated with sudden cardiac death due to prolongation of QT intervals and subsequent cardiac risks…
- Trial name
- AZI (NCT01323582)
- Testing
- Erythromycin, Azithromycin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Florida
Dry Eye Disease
Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease
SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734210
- Testing
- 0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate
- Where
- 28 sites in United States
- Volunteers
- 139 people
- Sponsor
- Surface Ophthalmics, Inc.
Breast Cancer, Cardiac Toxicity
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436566
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mayo Clinic
Postoperative Pain, Postoperative Vomiting and Nausea
Efficacy Side-effect Score (ESS): Development and Evaluation of a New Tool for Patients After Surgery
We hypothesized that better control of postoperative pain treatment and its side effects by monitoring ESS might influence the degree of mobility and morbidity in surgical patients and consequently reduce LOS.
- Conditions
- Postoperative Pain, Postoperative Vomiting and Nausea, Postoperative Complications, Mental Status Changes Postoperative
- Trial name
- ESScore (NCT02143128)
- Testing
- Efficacy Safety Score, Verbal Numeric Rating Scale
- Where
- 2 sites in Kazakhstan, Russia
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Vestre VikenHF Kongsberg Sykehus
Oxygen Deficiency, Desaturation of Blood
THRIVE Use in Pediatric Populations- Multi Site
THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
- Conditions
- Oxygen Deficiency, Desaturation of Blood, Hypoventilation, Anesthesia; Adverse Effect
- Trial name
- NCT04322994
- Testing
- Transnasal Humidified Rapid-Insufflation Ventilatory Echange
- Where
- 5 sites in United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Stanford University
Cisplatin Ototoxicity, Hearing Loss
Randomized Trial Comparison of Ototoxicity Monitoring Programs
This study involves research. Some chemotherapeutic drugs that can permanently reduce hearing are termed "ototoxic". One such drug is the chemotherapy called cisplatin.
- Trial name
- COMP-VA (NCT02099786)
- Testing
- COMP-VA, Standard of care
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury
Digoxin In Treatment of Alcohol Associated Hepatitis
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin…
- Conditions
- Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
- Trial name
- DIGIT-AlcHep (NCT05014087)
- Testing
- Intravenous digoxin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Breast Cancer, Chemotherapeutic Agent Toxicity
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
- Trial name
- NCT00751101
- Testing
- Nicotine patch
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Hypertension
Pharmacogenomic Evaluation of Antihypertensive Responses
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging.
- Trial name
- NCT00246519
- Testing
- Hydrochlorothiazide, Atenolol
- Where
- 3 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- University of Florida
Lymphoma, Childhood Lymphoma
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life.
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor
- Trial name
- UVA-Gen001 (NCT02624388)
- Testing
- Genistein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Virginia
Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide…
- Trial name
- NCT00853047
- Testing
- Telotristat etiprate, Octreotide LAR Depot
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Lexicon Pharmaceuticals
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Forehead Lines
A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines
Facial lines that develop from repeated facial expression, such as forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05152576
- Testing
- OnabotulinumtoxinA X
- Where
- 8 sites in United States
- Volunteers
- 124 people
- Sponsor
- Allergan
Fibromyalgia
Study of Gralise to Treat Fibromyalgia Patients
To determine Gralise in treating fibromyalgia pain: efficacy safety
- Trial name
- Gralise (NCT02052414)
- Testing
- Gabapentin ER
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- The Center for Clinical Research, Winston-Salem, NC
Breast Cancer Stages I Through III
The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients
The goal of this study is to determine if acupuncture improves multiple symptoms associated with chemotherapy on the MD Anderson Symptom Inventory (MDASI): nausea, vomiting, fatigue, anxiety, anorexia, pain, disturbed sleep…
- Trial name
- NCT01996410
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OhioHealth
Depression, Dysthymic Disorder
Duloxetine Treatment in Elderly With Dysthymia
Dysthymic disorder (DD) denotes chronic depression with fewer symptoms than major depressive disorder (MDD), and it affects ~ 2-4 % of adults with a similar prevalence in the elderly.
- Trial name
- NCT01852383
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Sarcoma, Chemotherapy-induced Nausea and Vomiting
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
The goal of this clinical research study is to learn how different doses of fosaprepitant may effect how ifosfamide-based chemotherapy is absorbed by the body.
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Trial name
- NCT01490060
- Testing
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Fibrosis, Kidney Failure
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled…
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Trial name
- NCT00744939
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- Bayer
Antidepressants Causing Adverse Effects in Therapeutic Use
Pharmacogenomic Testing in Primary Care
This is a 6-month randomized, wait-listed, controlled pilot trial conducted in 6 department of family medicine (DFM) clinics at the University of Michigan (UM).
- Trial name
- NCT03270891
- Testing
- PGx test
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan
Latent Tuberculosis, Human Immunodeficiency Virus
Doravirine, Rifapentine and Isoniazid Interaction
Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex.
- Conditions
- Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
- Trial name
- DORIIS (NCT03886701)
- Testing
- Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Walter K. Kraft